Search the Newsreel

Columbia Financial (CLBK) director Kuiken reports direct and indirect stock holdings

Columbia Financial, Inc. director James Michael Kuiken has filed a Form 3, disclosing his initial beneficial ownership in the company. The report indicates he directly holds 35,356 shares of Common Stock and indirectly holds 6,494 shares through a Stock Award V, as of July …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.

Lincoln National Corp. stock outperforms competitors on strong trading day

Lincoln National Corp. (LNC) stock increased by 2.68% to $45.28, outperforming competitors and ending a six-day losing streak on a strong trading day. This rise occurred as the S&P 500 Index and the Dow Jones Industrial Average also saw gains.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

SLC Agrícola (SLCE3): alavancagem no 2T26 preocupa analistas, mas melhora no guidance é bem-vista

Can Columbia Financial (CLBK) Run Higher on Rising Earnings Estimates?

Columbia Financial (CLBK) is showing strong potential for stock price growth due to significantly rising earnings estimates. Analysts have increased their optimism, leading to a favorable Zacks Rank #2 (Buy) for the company. This positive trend in earnings revisions suggests that CLBK, which has …

Columbia Sportswear’s Rain Jacket, on Sale for $35, Folds up Into Its Own Pocket

The Columbia Sportswear Women’s Switchback IV Jacket is currently on sale for $35, a 50% discount from its original price of $70. This lightweight, water-repellent rain jacket is designed to fold into its own pocket for easy portability and is available in multiple colorways …

Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The …

Americold Realty Trust (NYSE:COLD) Stock Price Expected to Rise, Scotiabank Analyst Says

Scotiabank has raised its price target for Americold Realty Trust (NYSE:COLD) from $15 to $16, maintaining a "sector perform" rating and indicating a potential upside of 5.43%. Despite this, the stock holds an average "Hold" rating from analysts with a consensus price target of …

Coca-Cola plans $106M Louisiana expansion

Coca-Cola UNITED announced a $

Bernstein reiterates Colgate-Palmolive stock rating on international strength By Investing.com

Bernstein SocGen Group maintained a Market Perform rating and $99.00 price target for Colgate-Palmolive (NYSE:CL), citing its strong leadership in Oral Care across international markets, especially Latin America. Despite some challenges in other categories and market share losses, the company's overall performance and gross …

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

Coca-Cola Europacific Partners plc : UBS is niet langer positief gestemd

UBS downgrades Coca-Cola Europacific Partners despite Q2 sales, volume beat

UBS downgraded Coca-Cola Europacific Partners (CCEP) to "neutral" from "buy" and trimmed its price target due to limited upside after a 19% rally year-to-date and re-rating to a 20% premium. This occurred despite CCEP beating Q2 organic revenue and volume growth estimates. While management …

Bernstein SocGen on Colgate-Palmolive Company (CL): 'Will International continue to sustain company growth?'

Bernstein SocGen Group analyst Cristian Rios reiterated a Market Perform rating and a $99.00 price target for Colgate-Palmolive Company (NYSE: CL). The article's headline questions whether international markets will continue to sustain the company's growth. The full article content is only available to premium …

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per …

Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com

Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock, part of a larger $150 million share repurchase program. The company will receive an initial delivery of 1,556,420 shares, representing about 80% …

UBS Downgrades Coca-Cola Europacific Partners to Neutral From Buy, Adjusts PT to $107 From $109

UBS has downgraded Coca-Cola Europacific Partners (CCEP) from a "Buy" rating to "Neutral." The firm also adjusted its price target for CCEP, lowering it from $109 to $107. This change reflects an updated outlook on the company's stock performance.

Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Pyxis Oncology, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net loss of $25.35 million, an increase from $18.35 million in the prior year, with a basic and …

Pyxis Oncology Q2 loss widens 38%, misses EPS estimate

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million, or ($0.40) per share, which widened by 38% year-over-year and missed analyst estimates due to a significant increase in general and administrative expenses. The company secured $50 million in new financing, extending its …

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Conference Call Transcript Operator: Greetings, and …

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary

Pyxis Oncology, Inc. reported its Q2 2026 financial results, showing $0 in revenue and a net loss of $25.35M, leading to a diluted EPS of $(0.40). This compares to Q2 2025 revenue of $2.82M and a net loss of $18.35M. The company highlighted continued …

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com

This article announces that Pyxis Oncology Inc. has filed a Form 8K on August 13. The brief piece provides no further details beyond the filing announcement. It includes stock market data and other Investing.com features.

Americold (COLD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations - Rich LelandChief Executive Officer - Rob ChambersChief Financial Officer - Chris Papa TAKEAWAYS Adjusted FFO per Share -- $0.35 for the second quarter, …

UBS verlaagt Coca-Cola Europacific Partners ondanks hogere Q2-omzet en volumes

Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on …

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by …

UBS Group Upgrades Lincoln Electric (NASDAQ:LECO) to Strong-Buy

UBS Group has upgraded Lincoln Electric (NASDAQ:LECO) to a "strong-buy" rating, joining other analysts with a generally positive outlook. The company recently reported strong quarterly earnings, beating analyst estimates with EPS of $2.93 and revenue of $1.22 billion. Institutional investors hold a significant stake …

Lincoln National Corporation (LNC) Stock Forecasts

An Argus report from August 12, 2026, has lowered the target price for Lincoln National Corporation (LNC) stock to $47.00. The company, which operates various insurance and retirement businesses, is currently trading at $45.28. The report provides an overview of LNC's operating segments, including …

Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program

Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price …

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its …

Pyxis Oncology expects two MICVO cancer-study data updates in 2026

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million but strengthened its financial position with a private placement of up to $114 million, extending its cash runway into Q2 2027. The company anticipates key clinical data readouts for its lead candidate, MICVO, …

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology (Nasdaq: PYXS) reported its second-quarter 2026 financial results, highlighting progress in its MICVO clinical development programs and an extended cash runway into Q2 2027 following a $114 million private placement. The company is set to release updated data from the MICVO Phase …

Why is Cullinan Oncology stock surging today? By Investing.com

Coca-Cola wird für mehr als Defensive bezahlt